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Abstract
Smaller expansions (41–54 CGG repeats) in the fragile X mental retardation 1 (FMR1) gene are termed ‘‘gray zone’’ alleles. Only recently has interest in these
expansions increased due to reporting of phenotypes unique to gray zone carriers or similar to those seen in individuals with larger expansions. As minimal research
has focused on gray zone expansions, this paper asks several questions related to this topic. These include the following: What is the definition of the gray zone? Is
there a risk of developing neurological signs in these carriers? Are there secondary gene effects that impact gray zone alleles or a biologic advantage to carrying these
repeats? How do we counsel patients with gray zone expansions? The answers to these questions will help to determine the significance of these expansions and
provide needed information to the research community and clinicians.
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Introduction
Trinucleotide repeat expansions (CGG) in the 59 untranslated
region of the fragile X mental retardation 1 (FMR1) gene are associated
with neurological signs in adults. Fragile X syndrome results from a full
expansion (.200 CGG repeats) in the gene and is the most common
inherited form of intellectual disability in boys. It is characterized by
decreased cognitive function, developmental anomalies, learning
disabilities, and emotional problems. Fragile X syndrome typically
presents in childhood and is not typically a progressive disorder with
tremor and ataxia. Repeat expansions in FMR1 of 55–200 CGG
repeats, or the premutation range, can manifest as the fragile X-
associated tremor/ataxia syndrome (FXTAS) or premature ovarian
insufficiency.1
FXTAS is a progressive neurological disorder with intention tremor,
cerebellar ataxia, and parkinsonism that was described initially in 2001
by our research group.2 FXTAS was discovered by a developmental
pediatrician who noticed that the grandparents of boys with fragile X
syndrome had tremor and balance problems. The classic phenotype is
typically seen in male premutation carriers over the age of 50, but it
has now been reported in female premutation carriers.2–5 FXTAS-like
phenotypes have also been reported in full mutation carriers.6–9 Other
features of FXTAS include peripheral neuropathy, lower limb
proximal muscle weakness, autonomic dysfunction, progressive
cognitive decline, and behavioral problems.10,11
Smaller expansions in FMR1 have been termed ‘‘gray zone’’ or
intermediate alleles based on the lower likelihood of the CGG repeat
increasing and causing fragile X syndrome in later generations. Gray
zone alleles have been reported to expand over two generations to a
full mutation, but typically it takes at least three generations.12–14
Due to the location of the FMR1 gene on the X chromosome, the
prevalence rates of repeat expansions are reported by sex. Mutations
leading to fragile X syndrome occur in one out of 4,000 males and one
out of 8,000 females.15–18 The premutation occurs in one out of 209
females and one out of 430 males.19,20 It is hypothesized that the
prevalence rates may be more proportional between men and women
than previously reported,21 but this has not been confirmed by studies.
The rate of FMR1 gray zone expansions in the general population is
variable, but large population studies report rates of 0.8% to 3.0% for
repeat sizes between 41 and 54.19,20,22 However, many of the
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epidemiological studies done have variable definitions of the gray zone,
ranging between 34 and 60 repeats making comparison across studies
difficult (Table 1).
Given the recent increasing interest in smaller expansions in the
FMR1 gene, this paper will summarize some of the key issues that need
to be addressed in this area. For the purposes of this paper, ‘‘gray
zone’’ terminology will be used. These issues impact not only fragile X
researchers; but also clinicians, genetic counselors, and geneticists who
will be seeing these individuals for clinical care.
What FMR1 repeat size should be defined as the gray zone?
The American College of Medical Genetics practice guidelines
define the intermediate zone or gray zone alleles as 41–60 CGG
repeats.23 However, 45–54 CGG repeats have been designated the
intermediate or gray zone by the laboratory practice committee of the
American College of Medical Genetics.24,25 More recent population
studies have used 41–54 repeats.19 This discrepancy in the definition of
the gray zone has become more important recently because several
studies have now reported phenotypes associated with gray zone or
intermediate allele sizes. It is not clear if the gray zone should be
defined based on the likelihood of expansion in later generations, by
associated phenotypes, or by underlying molecular abnormalities. It is
likely with more research, especially in regards to the molecular
consequences of smaller expansions, a clearer delineation of what
constitutes the gray zone or intermediate alleles will be apparent.
Is there a risk of developing neurological signs in individuals with
repeats from 41–54?
Until recently, FMR1 gray zone expansions (41–54 CGG repeats)
were not thought to be associated with disease or neurological signs. In
Table 1. Prevalence of Gray Zone Alleles in Population Studies
Author Defined
Gray Zone





Rousseau et al.56 35–54 Not reported Women 10,624 Canada 0.4
Dawson et al.57 40–59 Newborns Men and
women
2,000 Spain 2.7
Zhong et al.58 41–54 Not reported Men 56 USA 1.7
Spence et al.59 40–59 (Pregnant women of advanced
maternal age)
Women 745 USA 2.2
Drasinover et al.52 50–55 Not reported Women 10,587 Israel 0.5
Dombrowski et al.60 40–54 Not reported Men 10,572 Canada 0.3
Penagarikano et al.22 41–54 Not reported Men 158 Spain 3.2
Cronister et al.61 45–54 Not reported Women 29,103 USA 0.7
Tzeng et al.62 45–54 Newborns Boys 10,046 Taiwan 0.7
Metcalfe et al.63 45–54 .18 years Women 338 Australia 0.7






45–54 Newborns Boys and
girls
5,267 Spain 3.8
Otsuka et al.65 40–50 Not reported Men and
women
946 Japan 0.6
Tassone et al.19 45–54 Newborns Boys and
girls
14,207 USA 1.2
Seltzer et al.66 45–54 67–68 years Men and
women
6,747 USA 2.6
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2000, a 5-year survey of special education boys in the United Kingdom
showed an excess of gray zone expansions.26 However, this result has
not been replicated in other populations.27 In 2006, it was recognized
that premature ovarian insufficiency, which is associated with
premutation expansions, is also present in gray zone expansion
carriers.28,29
More recently, our group found 5.5% of parkinsonism patients
(n5273) overall in movement disorder clinics were FMR1 gray zone
carriers and that 12% of the female parkinsonism patients (11/98) had
gray zone alleles.30 Clinical characteristics of the gray zone carriers
included classical features of Parkinson disease (PD), with most patients
having asymmetric rest tremor, bradykinesia, and rigidity. In addition,
gray zone carriers were dopamine responsive and some had evidence
of motor fluctuations and dyskinesia from dopaminergic medications.
However, some of the gray zone carriers with parkinsonism had
features uncommon in idiopathic PD, to include kinetic tremor and
mild gait ataxia. Although women with parkinsonism were the most
highly represented among the gray zone carriers in this screening
study, the rate of FMR1 gray zone expansions was also increased in
women with ataxia (n575) compared to controls (n5115): 9% vs.
4.3% (p,0.001). Other clinical features included a higher rate of
anxiety in the gray zone carrier women, which is a common feature
seen in premutation (55–200 CGG) carrier women, with or without
FXTAS.31
Two other groups have reported increased gray zone expansions in
parkinsonism populations. In an Australian cohort, 228 males with PD
or parkinsonism seen in a movement disorder clinic were screened.32
Compared to newborn males screened at the same institution (n5576),
there was an increased prevalence of gray zone expansions (8% vs.
3.4%, p50.012). A second group in China screened 360 patients with
parkinsonism and 295 age and sex-matched controls and found similar
results, with an increased rate of FMR1 gray zone expansions in female
cases (n5147) compared to female controls (n5122; 6.8% vs. 0,
p,0.05).33 However, no association was seen in the Chinese men with
parkinsonism. An additional group found two men with PD and
marked cognitive decline with 41 and 46 CGG repeats and postulate
that a possible association may exist in phenotypes on the PD
spectrum.34
In contrast, other studies have not shown an increase in gray zone or
intermediate alleles in similar populations.35 The rates reported are
variable, with 1.2–1.9% of male parkinsonism patients, 3% of Asian
late-onset PD patients, and 2.3% of Italian female parkinsonism
patients having gray zone alleles.36–38 Although all of these studies
reported that these rates are the same as the population rate, women
have been excluded in many of the screens due to the definition of
FXTAS being seen initially in male premutation carriers only. Given
the differences of these study results in sex, ethnicity, and control
populations, defining the true association in a community-based
unbiased sample is important, but unlikely to be accomplished as
parkinsonism affects such a small percentage of the population.
Population screening studies would also suggest that gray zone
alleles are more highly represented in ataxia phenotypes in general,
including multiple system atrophy, with rates as high as 8%.39
However, the prevalence rates are difficult to compare across studies
given the different study designs, with varying types of ataxia patients
included, mixed populations, differing ages, and lack of collected
controls.
A FXTAS-like phenotype has now been reported in gray zone
carriers. A study of a family of FMR1 repeat expansion carriers with
broad clinical involvement describes a gray zone carrier with 52 CGG
repeats with subtle tremor and balance problems, but milder than
what is seen in FXTAS.40 Imaging was not reported. In addition, three
gray zone carriers who meet clinical diagnostic criteria for FXTAS
have been described by our group41 and two additional cases by a
second group.42 Like the earlier studies, which may expand the
phenotype of FXTAS, better characterization of gray zone carriers
with neurological signs and symptoms may suggest that these
individuals also have a FXTAS-like phenotype or a neurological
phenotype more similar to PD.
Do individuals with a gray zone expansion and parkinsonism
have a different entity altogether from PD?
In order to investigate differences in parkinsonism in FMR1 gray
zone expansions compared to typical PD, our group conducted a study
to determine if presynaptic dopamine deficits were present in the
FMR1 repeat expansion carriers. Dopamine transporter imaging with
[123I] b-CIT (2b-carbomethoxy-3b-(4-iodophenyl) tropane) SPECT
(single photon emission computed tomography) was performed on two
patients with parkinsonism and a gray zone expansion.30,43 Both
patients had normal imaging despite having parkinsonism, meeting
clinical criteria for PD, and responding to dopaminergic therapy. This
suggests that parkinsonism associated with FMR1 repeat expansion
may be different mechanistically than typical PD.
Are pathologic changes or neuroimaging abnormalities present in
gray zone carriers with neurological signs?
Gray zone carriers of 45–54 CGG repeats can have up to 1.5-fold
increase in FMR1 mRNA, with transcript levels of FMR1 mRNA
starting to increase at just 39 CGG repeats.44 This increase in FMR1
mRNA is seen to a greater extent (two–fourfold) in carriers of
premutation size expansions and has been postulated to account for a
‘‘toxic gain of function’’ mechanism leading to neurodegeneration in
FXTAS.45 Higher levels of mRNA correlate positively with degree of
neuropathology46 and peripheral neuropathy47 in affected premuta-
tion carriers, which supports this hypothesis. It is not clear whether a
similar mechanism accounts for neurological signs in gray zone
carriers or whether other pathophysiology is present.
There is a paucity of neuroimaging data reported in gray zone
carriers. Loesch et al.48 reported a 71-year-old male with a PD
phenotype and dementia who had T2 hyperintensity in the basis
pontis. Abnormalities in the pontine fibers that are entering or exiting
the cerebellum, especially in the middle cerebellar peduncle (MCP),
may be evidenced in premutation carriers as a hyperintensity in the
MCP and has been associated with FXTAS.49
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Are other secondary gene effects responsible for the phenotypes
seen in gray zone expansion carriers?
A study that examined patients with gray zone or low end
premutation expansions (40–85 CGG repeats) showed that motor
dysfunction and cognitive decline were correlated with CGG repeat
size, levels of antisense FMR1, and cytochrome C1 (CYC1) mRNA.50 The
antisense transcript has been shown to be elevated in premutation
carriers and may be a secondary gene effect that increases the
likelihood of manifestation of neurological signs in FMR1 expansion
carriers. The authors showed that the relationship between CGG
repeat size, antisense transcript levels, and phenotype may be
mediated through mitochondrial dysfunction due to elevated levels
of CYC1 expression (a gene which is expressed during mitochondrial
expansion) and depletion of the nicotinamide adenine dinucleotide,
reduced dehydrogenase subunit 1 mitochondrial gene.
However, there may be other gene effects that account for
phenotypic abnormalities. AGG trinucleotide interruptions (typically
separated by 9–11 CGG repeats) within the CGG-repeat element of
the FMR1 gene are known to disrupt the otherwise pure CGG-repeat
motif. Normal FMR1 alleles typically possess two or three AGG
interruptions, premutation alleles generally possess two or less
interruptions, and larger premutation alleles tend to have fewer
AGG interruptions. The loss of AGG interruptions is thought to
increase the probability of transmission of a full mutation allele.51
Some researchers postulate that a lack of AGG interruptions may
increase the likelihood of neurological symptoms in premutation
carriers, but this has not yet been studied formally. The role of a lack of
AGG interruptions in relation to the phenotypes of the gray zone
carriers is even less clear.
Is there a biologic advantage to carrying gray zone alleles?
In a study testing 10,587 healthy females, there was a significant
increase in the transmission of an abnormal allele between 51–
60 CGG repeats compared to transmission of a normal allele.52 This
increase in transmission was not seen in carriers of .60 CGG repeats.
This intriguing result may suggest that there is a genetic advantage for
the abnormal allele in this range and that there is non-random
transmission of the abnormal allele to offspring. Earlier studies showed
that in mothers who carried higher premutation alleles (typi-
cally .70 CGG repeats), the normal allele was transmitted more
frequently.53
How do you counsel a patient with a gray zone expansion?
Although some guidelines for genetic counseling would suggest that
there are no consistent associations between phenotypes and gray zone
alleles,54 presenting a more measured approach might be considered
for individuals with smaller expansions. This could mean discussing
data that suggest that phenotypes may be associated; additional studies
in this area will provide more certainty. These neurological phenotypes
include FXTAS-like signs, parkinsonism, and ataxia. Given the clear
association of a lack of AGG interruptions with FMR1 repeat
expansion in subsequent generations (repeat instability), risk estimates
of fragile X-associated disorders in families who carry smaller
expansions (45–69 CGG) may be more accurate with characterization
of the AGG structure in an individual patient.55
Implications
The knowledge concerning gray zone FMR1 repeat expansions is
increasing, but almost all questions related to the genotype are yet to
be definitively answered. Recommendations for future research in the
area of the FMR1 gray zone include determining a consistent
definition of the repeat size of the genotype in the literature (41–54
vs. 45–54), consistent definition of the name (intermediate vs. gray
zone), defining the clinical ramifications of a repeat expansion,
describing the underlying pathology and imaging of these repeat
expansion carriers, and the consequences for families. This paper
focused mostly on neurological issues in gray zone expansion carriers,
but phenotypes in other realms that are seen in premutation carriers,
such as psychiatric, cognitive, and endocrine, should be investigated as
well. A multifaceted program of research, similar to those created for
the larger expansion carriers, would be ideal to answer some of these
key questions.
There are several barriers that need to be overcome in carrying out
this work. Cascade testing in families with fragile X children will not
typically yield gray zone expansion carriers, who may be great
grandparents. Instead, researchers who do population screening will
need to identify and recruit those individuals with gray zone
expansions who were ascertained in order to pool enough affected
individuals to carry out the needed research. Collaborating with other
researchers, which may include experts outside of neurology, who do
screening or epidemiologic studies, will be critical to reach needed
sample sizes. This will allow the field to move beyond case studies or
clinic-based methods of study. Genetic counselors will also need to be
educated to refer patients who are identified with gray zone expansions
in order to facilitate local recruitment for these studies. Finally,
recruiting more physicians who specialize in adult diseases into fragile
X-associated disorders research will enhance studies in these patients,
as symptoms are more likely to manifest in adult years similar to the
premutation carriers.
In the past, with the discovery of FXTAS, research regarding the
premutation rapidly progressed. It is the hope of many of the clinicians
and researchers in the field that similar resources will enable quick
resolution of some of the issues raised in this paper. Fragile X research
is a highly collaborative enterprise, with many of the large centers and
clinics working across institutions, disciplines, and countries. This is
likely to speed discovery and, hopefully, enhance the likelihood these
issues will be resolved in a timely manner.
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